IP Library › Granted Patent US 12,404,305
Granted Patent B2
US 12,404,305 · App. 18/069,151 · Granted Sep 2, 2025

Chimeric polypeptides and uses thereof

Inventors: Stuart A. Sievers (Van Nuys, CA); Jed J. W. Wiltzius (Winchester, MA)
Assignee: Kite Pharma, Inc.
C07K14/003A61K40/11A61K40/31A61K40/4211A61K47/65A61P35/02C07K4/00C07K7/06C07K7/08C07K16/2803C07K16/44C12N15/62C12N15/85C07K2317/32C07K2317/34C07K2317/622C07K2319/40
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,404,305
App. No.
18/069,151
Granted
Sep 2, 2025
Kind
B2
Abstract

The invention provides novel peptides (e.g., linkers) and polypeptide compositions comprising the linkers (e.g., fusion proteins) and methods of using the polypeptide compositions. Peptides (e.g., linkers) are useful as tags and for engineering fusion proteins (e.g., antigen binding molecules, scFv). Polypeptide linkers described herein facilitate flexibility of linked peptides allowing for proper folding, conformation and reduced immunogenicity.

Claims (11)

1. A fusion protein comprising:

a first polypeptide and a second polypeptide covalently linked by a peptide comprising the amino acid sequence selected from the group consisting of:

(i) GGGSGKPGSGEGGGS (SEQ ID NO: 7);

(ii) GGGSGKPGSGEGGGGS (SEQ ID NO: 8);

(iii) GGGGSGKPGSGGGGS (SEQ ID NO: 9);

(iv) GGGGSGKPGSGEGGS (SEQ ID NO: 10)

(v) GGGGSGKPGSGEGGGS (SEQ ID NO: 11); and

(vi) GGGGSGKPGSGEGGGGS (SEQ ID NO: 12).

2. The fusion protein of claim 1 , wherein the first polypeptide comprises a light chain variable domain and the second polypeptide comprises a heavy chain variable domain.

3. The fusion protein of claim 2 , wherein the fusion protein is an scFv.

4. The peptide fusion protein of claim 1 , wherein the fusion protein is an antigen binding molecule.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 30, 2023
From: SIEVERS, STUART A.; WILTZIUS, JED J.W.
To: KITE PHARMA, INC.
Reel/Frame 063792/0893 →
Continuity (4)
Continuation 15929737 · May 19, 2020
Continuation 16138331 · Sep 21, 2018
Provisional Application 62562223 · Sep 22, 2017
Related Publication 20230287054A1 · Sep 14, 2023
References Cited (79)
US 5728388A · Terman · 1998 [cited by applicant]
US 6541610B1 · Smith · 2003 [cited by applicant]
US 6727225B2 · Wiley · 2004 [cited by applicant]
US 6728388B1 · Nageno et al. · 2004 [cited by applicant]
US 7056683B2 · Ting · 2006 [cited by applicant]
US 10501775B2 · Wiltzius · 2019 [cited by examiner]
US 10844371B2 · Wiltzius · 2020 [cited by examiner]
US 11572388B2 · Wiltzius · 2023 [cited by examiner]
US 11608517B2 · Wiltzius · 2023 [cited by examiner]
US 20020006409A1 · Wood · 2002 [cited by applicant]
US 20060035387A1 · Wagner et al. · 2006 [cited by applicant]
US 20060275868A1 · Smith · 2006 [cited by applicant]
US 20070148739A1 · Jones et al. · 2007 [cited by applicant]
US 20110020345A1 · Herring et al. · 2011 [cited by applicant]
US 20130287748A1 · June et al. · 2013 [cited by applicant]
US 20140050708A1 · Powell et al. · 2014 [cited by applicant]
US 20140072581A1 · Dixit et al. · 2014 [cited by applicant]
US 20140086907A1 · Shah · 2014 [cited by applicant]
US 20140099309A1 · Powell, Jr. et al. · 2014 [cited by applicant]
US 20140154228A1 · Volk et al. · 2014 [cited by applicant]
US 20140227237A1 · June et al. · 2014 [cited by applicant]
US 20140227264A1 · Hamilton et al. · 2014 [cited by applicant]
US 20160017047A1 · Poma et al. · 2016 [cited by applicant]
US 20160137711A1 · Schellenberger et al. · 2016 [cited by applicant]
US 20160152723A1 · Chen · 2016 [cited by examiner]
US 20160208018A1 · Chen et al. · 2016 [cited by applicant]
US 20180280437A1 · Wiltzius · 2018 [cited by examiner]
JP 2014526254A · 2014 [cited by applicant]
JP 2015531751A · 2015 [cited by applicant]
WO WO98036087A1 · 1998 [cited by applicant]
WO WO02059258A2 · 2002 [cited by applicant]
WO WO04044168A2 · 2004 [cited by applicant]
WO WO2008081035A1 · 2008 [cited by applicant]
WO WO12106281A2 · 2012 [cited by applicant]
WO WO2012138475A1 · 2012 [cited by applicant]
WO WO2016126950A1 · 2016 [cited by applicant]
WO WO17076916A1 · 2017 [cited by applicant]
Barrios, Y. et al. (2004) “Length of the antibody heavy chain complementarity determining region 3 as a specificity-determining factor” J Molecular Recognition 17:332-338. [cited by applicant]
Bird, R.E. et al. (1988) “Single-chain antigen-binding proteins” Science 242:423-426. [cited by applicant]
Bruggemann, M. et al. (1997) “Production of human antibody repertoires in transgenic mice” Curr. Opin. Biotechnol. 8:455-458. [cited by applicant]
Cheung, R.C. et al. (1990) “Epitope-specific antibody response to the surface antigen of duck hepatitis B virus in infected ducks” Virology 176(2):546-552. [cited by applicant]
Dayhoff, M.O. et al. (1978) “22. A Model of Evolutionary Change in Proteins” Atlas of Protein Sequence and Structure 5:345-352. [cited by applicant]
Decision of Final Rejection dated Dec. 7, 2021 for Japanese Appl. No. 2020-516415. [cited by applicant]
Devereux, J. et al. (1984) “A comprehensive set of sequence analysis programs for the VAX” Nucl. Acid Res. 12(1):387-395. [cited by applicant]
Edwards, B.M. et al. (2003) “The Remarkable Flexibility of the Human Antibody Repertoire; Isolation of Over One Thousand Different Antibodies to a Single Protein, BLyS” J Mol Biol. 334(1):103-118. [cited by applicant]
Examination Report dated Mar. 24, 2021 for Australian Appl. No. 2018338192. [cited by applicant]
Examination Report dated Dec. 2, 2021 for Australian Appl. No. 2018338192. [cited by applicant]
Henikoff, S. et al. (1992) “Amino acid substitution matrices from protein blocks” Proc Natl Acad Sci. USA 89(22):10915-10919. [cited by applicant]
Huston, J.S. et al. (1988) “Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in [cited by applicant]
Intl. Search Report—Written Opinion dated Nov. 20, 2018 for PCT Intl. Appl. No. PCT/US2018/052184. [cited by applicant]
Kirkland, T.N. et al. (1986) “Analysis of the fine specificity and cross-reactivity of monoclonal anti-lipid A antibodies” J. Immunol. 137(11):3614-3619. [cited by applicant]
Lloyd, C. et al. (2009) “Modelling the human immune response: performance of a 10 [cited by applicant]
MacCallum, R.M. et al. (1996) “Antibody-antigen Interactions: Contact Analysis and Binding Site Topography” J Mol Biol. 262:732-745. [cited by applicant]
Moldenhauer, G. et al. (1990) “Identity of HML-1 antigen on intestinal intraepithelial T cells and of B-ly7 antigen on hairy cell leukaemia” Scand. J. Immunol. 32(2):77-82. [cited by applicant]
Morel, G.A. et al. (1988) “Monoclonal antibodies to bovine serum albumin: affinity and specificity determinations” Molecular Immunol. 25(1):7-15. [cited by applicant]
NCBI Blast search of Seq Id No. 10 downloaded Nov. 14, 2019 (Year: 2019). [cited by applicant]
NCBI Blast search of Seq Id No. 11 downloaded Nov. 14, 2019 (Year: 2019). [cited by applicant]
NCBI Blast search of Seq Id No. 12 downloaded Nov. 14, 2019 (Year: 2019). [cited by applicant]
NCBI Blast search of Seq Id No. 17 downloaded Nov. 14, 2019 (Year: 2019). [cited by applicant]
NCBI Blast search of Seq Id No. 18 downloaded Nov. 14, 2019 (Year: 2019). [cited by applicant]
NCBI Blast search of Seq Id No. 19 downloaded Nov. 14, 2019 (Year: 2019). [cited by applicant]
NCBI Blast search of Seq Id No. 20 downloaded Nov. 14, 2019 (Year: 2019). [cited by applicant]
NCBI Blast search of Seq Id No. 5 downloaded Nov. 14, 2019 (Year: 2019). [cited by applicant]
NCBI Blast search of Seq Id No. 6 downloaded Nov. 14, 2019 (Year: 2019). [cited by applicant]
NCBI Blast search of Seq Id No. 7 downloaded Nov. 14, 2019 (Year: 2019). [cited by applicant]
NCBI Blast search of Seq Id No. 8 downloaded Nov. 14, 2019 (Year: 2019). [cited by applicant]
NCBI Blast search of Seq Id No. 9 downloaded Nov. 14, 2019 (Year: 2019). [cited by applicant]
Nicholson, I.C. et al. (1997) “Construction and characterisation of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukaemia and lymphoma” Mol. Immunol. 34(16-17):1157-1165. [cited by applicant]
Office Action dated Feb. 11, 2021 for Canadian Appl. No. 3,076,099. [cited by applicant]
Office Action dated Mar. 16, 2021 for Japanese Appl. No. 2020-516415. [cited by applicant]
Office Action dated Mar. 31, 2021 for European Appl. No. 18788941.5. [cited by applicant]
Office Action dated Jan. 21, 2022 for Canadian Appl. No. 3,076,099. [cited by applicant]
Office Action dated Mar. 14, 2022 for Korean Appl. No. 10-2020-7011148. [cited by applicant]
Office Action dated Nov. 21, 2022 for Canadian Appl. No. 3,076,099. [cited by applicant]
Rudikoff, S. et al. (1982) “Single amino acid substitution altering antigen-binding specificity” Proc Natl Acad Sci USA 79:1979. [cited by applicant]
Seet, C.S. et al. (2017) “Generation of mature T cells from human hematopoietic stem/progenitor cells in artificial thymic organoids” Nat Methods. 14(5):521-530. [cited by applicant]
Stahli, C. et al. (1983) “Distinction of epitopes by monoclonal antibodies” Methods in Enzymology 92:242-253. [cited by applicant]
Wu, H. et al. (1999) “Humanization of a Murine Monoclonal Antibody by Simultaneous Optimization of Framework and CDR Residues” J Mol Biol. 294:151-162. [cited by applicant]
Yusakul, G. et al. (2016) “Effect of linker length between variable domains of single chain variable fragment antibody against daidzin on its reactivity” Biosci Biotechnol Biochem. 80(7):1306-1312. [cited by applicant]